Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Van Luan PhamTuan Anh LeCam Phuong PhamThi Thai Hoa NguyenAnh Tu DoTuan Khoi NguyenMinh Hai NguyenThi Anh Thu HoangDinh Thy Hao VuongDac Nhan Tam NguyenVan Khiem DangThi Oanh NguyenThi Huyen Trang VoHung Kien DoHa Thanh VuThi Thuy Hang NguyenVan Thai PhamLe Huy TrinhKhac Dung NguyenHoang Gia NguyenMinh Cong TruongTran Minh Chau PhamThi Bich Phuong NguyenPublished in: Therapeutic advances in medical oncology (2024)
Afatinib is effective for locally advanced metastatic NSCLC with uncommon EGFR mutations. Patients with G719X, compound G719X-S768I mutations, and tolerated doses of 20 or 30 mg had a longer median TTF than those with other mutations.